SNRK-AS1: A Potential Drug Target and Biomarker (G100873954)

Target Name: SNRK-AS1

NCBI ID: G100873954

SNRK-AS1

Other Name(s): SNRK antisense RNA 1

SNRK-AS1: A Potential Drug Target and Biomarker

Suvrat Pal, Ph.D., DVM, is a computational biologist and a leading expert on RNA-protein interactions at the University of California, San Diego. In recent years, his research has focused on understanding the role of RNA-protein interactions in diseases such as cancer, neurodegenerative diseases, and autoimmune disorders. One of his ongoing research is on the study of SNRK-AS1, a protein which has the potential to be a drug target or biomarker.

SNRK-AS1: The Name and Background

SNRK-AS1, or Small Nucleolar RRNA-AS1, is a non-coding RNA molecule that plays a critical role in regulating gene expression in the cell. It is a part of the 28S ribosome complex, which is responsible for producing proteins from mRNA templates. SNRK-AS1 is composed of 21 non-coding RNA subunits that are arranged in a specific structure known as the nucleolar Complex II (NCI) complex.

SNRK-AS1 functions as a negative regulator of gene expression by binding to specific mRNAs and preventing their translation into proteins. This process is known as post-transcriptional regulation (PTR) and is a common mechanism used by many eukaryotic organisms to regulate gene expression. SNRK-AS1 has been shown to interact with multiple protein partners, including histone modifications, non-coding RNAs, and other ribosomal proteins.

Potential Drug Target: SNRK-AS1 as a Chaperone

SNRK-AS1 has been identified as a potential drug target due to its unique mechanism of post-transcriptional regulation. By preventing mRNAs from being translated into proteins, SNRK-AS1 can be thought of as a chaperone that functions to regulate gene expression. This is similar to the function of histone-modifying enzymes, which are known to play a similar role in regulating gene expression.

One of the challenges in targeting SNRK-AS1 as a drug is its high degree of complexity and the fact that it is involved in multiple cellular processes. To overcome this challenge, researchers have used a combination of computational and experimental techniques to study the molecular mechanisms underlying SNRK-AS1 function.

Biomarker: SNRK-AS1 as a Potential Antigen

SNRK-AS1 has also been identified as a potential biomarker for cancer. In cancer cells, SNRK-AS1 levels often increase and are associated with poor prognosis. This is because SNRK-AS1 functions as a negative regulator of gene expression, and when it is expressed at high levels, it can prevent mRNAs from being translated into proteins, leading to a reduction in the levels of available proteins that can perform critical cellular functions.

Research has also shown that SNRK-AS1 is expressed at higher levels in cancer cells compared to healthy cells, and that downregulation of SNRK-AS1 has been shown to enhance the sensitivity of cancer cells to chemotherapy. These findings suggest that SNRK-AS1 may be an attractive biomarker for cancer diagnosis and treatment.

Conclusion

SNRK-AS1 is a non-coding RNA molecule that plays a critical role in regulating gene expression in the cell. Its unique mechanism of post-transcriptional regulation as a chaperone has led it to be identified as a potential drug target, and its potential as a biomarker for cancer has further increased its potential impact on the field of medicine. Further research is needed to fully understand the molecular mechanisms underlying SNRK-AS1 function and its potential as a drug target and biomarker.

Protein Name: SNRK Antisense RNA 1

The "SNRK-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNRK-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets